ArticleEJNMMI physics2017
3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.
Article in EJNMMI physics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Trial
- Review
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle forEJNMMI physics · 2022Article
- Antibody Conjugates for Sarcoma Therapy: How Far along Are We?Biomedicines · 2021Review
- WNT Signaling as a Therapeutic Target for Glioblastoma.International journal of molecular sciences · 2021Review
- Quantification of internal dosimetry in PET patients: individualized Monte Carlo vs generic phantom-based calculations.Medical physics · 2020Article
- WNT Signaling in Cancer Immunosurveillance.Trends in cell biology · 2019Review
- Image-based SPECT calibration based on the evaluation of the Fraction of Activity in the Field of View.EJNMMI physics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backroundRadiolabeled OTSA101, a monoclonal antibody targeting synovial sarcoma (SS) developed by OncoTherapy Science, was used to treat relapsing SS metastases following a theranostic procedure: in case of significant
resultsBiodistribution and tracer quantification were analyzed on repeated SPECT/CT acquisitions performed after injection of
conclusions3D dosimetry results can explain the observed toxicity and tumors response. Despite an intense visual
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.